- Previous Close
32.30 - Open
29.15 - Bid 29.70 x --
- Ask 29.80 x --
- Day's Range
29.15 - 30.15 - 52 Week Range
29.15 - 35.85 - Volume
1,013,299 - Avg. Volume
110,856 - Market Cap (intraday)
5.94B - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
16.05 - EPS (TTM)
1.85 - Earnings Date May 1, 2025 - May 5, 2025
- Forward Dividend & Yield 1.20 (3.72%)
- Ex-Dividend Date Aug 20, 2024
- 1y Target Est
--
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. Its products portfolio includes various salt and seawater chemical products; bath salt, bath salt milk, salt soap, algae soap, and shampoo; beverage and raw drinking water; skin care; toothpaste, salt mouthwash, and eye glass care solution; salt for washing fruits and vegetables; and food and food additives. The company also manufactures western medicine, environmental pharmaceuticals, and cosmetics. In addition, it imports and exports daily necessities and cosmetic products. Further, the company is involved in the provision, introduction, and management consulting of industrial salt technology. Taiyen Biotech Co., Ltd. was founded in 1952 and is based in Tainan, Taiwan.
www.tybio.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1737.TW
View MorePerformance Overview: 1737.TW
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1737.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1737.TW
View MoreValuation Measures
Market Cap
6.46B
Enterprise Value
4.83B
Trailing P/E
17.46
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.00
Price/Book (mrq)
0.97
Enterprise Value/Revenue
1.49
Enterprise Value/EBITDA
7.35
Financial Highlights
Profitability and Income Statement
Profit Margin
11.47%
Return on Assets (ttm)
2.59%
Return on Equity (ttm)
4.80%
Revenue (ttm)
3.24B
Net Income Avi to Common (ttm)
371.52M
Diluted EPS (ttm)
1.85
Balance Sheet and Cash Flow
Total Cash (mrq)
1.9B
Total Debt/Equity (mrq)
3.08%
Levered Free Cash Flow (ttm)
293.46M